Sagent Pharmaceuticals Inc (SGNT) was Reiterated by RBC Capital Mkts to “Outperform” while Lowering the Price Target of the company shares to $ 20 from a previous price target of $28 . RBC Capital Mkts advised their investors in a research report released on May 4, 2016.
On the company’s financial health, Sagent Pharmaceuticals Inc reported $0.02 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on May 3, 2016. Analyst had a consensus of $0.00. The company had revenue of $67.80 million for the quarter, compared to analysts expectations of $74.22 million. The company’s revenue was down -17.9 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.04 EPS.
Sagent Pharmaceuticals Inc opened for trading at $11.72 and hit $11.93 on the upside on Monday, eventually ending the session at $11.76, with a gain of 1.03% or 0.12 points. The heightened volatility saw the trading volume jump to 4,26,382 shares. Company has a market cap of $386 M.
Sagent Pharmaceuticals Inc. (Sagent) formerly Sagent Holding Co. is an injectable pharmaceutical company that develops and sources products that the Company sells primarily in the United States. Sagent focuses primarily on generic injectable pharmaceuticals. Sagent offers its customers a range of products across anti-infective oncolytic and critical care indications in a variety of presentations including single- and multi-dose vials pre-filled ready-to-use syringes medical devices and premix bags. As of October 31 2010 Sagent marketed 21 products. The Company has a 50/50 joint venture known as Sagent Strides LLC (Sagent Strides) with a subsidiary of Strides Arcolab Limited (Strides) which is an Indian manufacturer of finished pharmaceutical products.